Last reviewed · How we verify
"Priming" dose of ribavirin given
"Priming" dose of ribavirin given is a Nucleoside analog antiviral Small molecule drug developed by Göteborg University. It is currently in Phase 3 development for Chronic hepatitis C (in combination with interferon or direct-acting antivirals), Severe respiratory syncytial virus (RSV) infection, Hemorrhagic fever with renal syndrome.
Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate metabolism and viral polymerase function.
Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by interfering with guanosine triphosphate metabolism and viral polymerase function. Used for Chronic hepatitis C (in combination with interferon or direct-acting antivirals), Severe respiratory syncytial virus (RSV) infection, Hemorrhagic fever with renal syndrome.
At a glance
| Generic name | "Priming" dose of ribavirin given |
|---|---|
| Sponsor | Göteborg University |
| Drug class | Nucleoside analog antiviral |
| Target | Viral RNA-dependent RNA polymerase; IMPDH (inosine monophosphate dehydrogenase) |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ribavirin is converted intracellularly to its active triphosphate form, which inhibits inosine monophosphate dehydrogenase (IMPDH), depleting guanosine nucleotides essential for viral RNA synthesis. It also directly inhibits viral RNA-dependent RNA polymerase and can cause mutagenesis of viral genomes. The 'priming' dose refers to an initial loading dose used to rapidly achieve therapeutic concentrations.
Approved indications
- Chronic hepatitis C (in combination with interferon or direct-acting antivirals)
- Severe respiratory syncytial virus (RSV) infection
- Hemorrhagic fever with renal syndrome
Common side effects
- Hemolytic anemia
- Teratogenicity/embryocidal effects
- Fatigue
- Headache
- Dyspnea
- Nausea
- Insomnia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- "Priming" dose of ribavirin given CI brief — competitive landscape report
- "Priming" dose of ribavirin given updates RSS · CI watch RSS
- Göteborg University portfolio CI
Frequently asked questions about "Priming" dose of ribavirin given
What is "Priming" dose of ribavirin given?
How does "Priming" dose of ribavirin given work?
What is "Priming" dose of ribavirin given used for?
Who makes "Priming" dose of ribavirin given?
What drug class is "Priming" dose of ribavirin given in?
What development phase is "Priming" dose of ribavirin given in?
What are the side effects of "Priming" dose of ribavirin given?
What does "Priming" dose of ribavirin given target?
Related
- Drug class: All Nucleoside analog antiviral drugs
- Target: All drugs targeting Viral RNA-dependent RNA polymerase; IMPDH (inosine monophosphate dehydrogenase)
- Manufacturer: Göteborg University — full pipeline
- Therapeutic area: All drugs in Virology/Infectious Disease
- Indication: Drugs for Chronic hepatitis C (in combination with interferon or direct-acting antivirals)
- Indication: Drugs for Severe respiratory syncytial virus (RSV) infection
- Indication: Drugs for Hemorrhagic fever with renal syndrome
- Compare: "Priming" dose of ribavirin given vs similar drugs
- Pricing: "Priming" dose of ribavirin given cost, discount & access